Hi xxxx,no problem. It’s because there have been previous programs for Angelman in thePsychiatry division, whereas there is not that precedent for the other two. Itwas the same situation for Fragile X. In recent times the Office ofNeuroscience was created to supervise both, so there is now close co-operation.The feedback we received on all three protocols was very similar.
Regards,Jon
Jon Pilcher
Chief Executive Officer
Neuren Pharmaceuticals
jpilcher@neurenpharma.com
Ann: Q4 2021 quarterly activity and cash flow report, page-18
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1215 | $12.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.54 | 804 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |